文献速递骨肿瘤

软骨肉瘤区域淋巴结受累与较差生存相关:SEER分析

Regional Lymph Node Involvement Is Associated With Poorer Survivorship in Patients With Chondrosarcoma: A SEER Analysis.
PubMed 文献 · Clin Orthop Relat Res · 2019-01-01

该研究基于SEER数据库1988至2015年数据,分析3374例软骨肉瘤患者,区域淋巴结受累报告率为1.3%。淋巴结受累者5年总生存率为28%,无受累者为77%,调整混杂后淋巴结受累与较差生存独立相关(HR 2.20)。

要点

  • 软骨肉瘤区域淋巴结受累报告率为1.3%(44/3374)。
  • 淋巴结受累者5年总生存率28% vs 无受累者77%(P < 0.001)。
  • 调整后淋巴结受累与较差生存独立相关(HR 2.20)。

核心结论

  • SEER数据库中软骨肉瘤区域淋巴结受累的报告率为1.3%。
  • 有区域淋巴结转移的软骨肉瘤患者预后较无报告淋巴结转移者差。
  • 作者认为临床医生应更仔细检查软骨肉瘤患者的淋巴结转移情况。
  • 未来需要研究评估潜在治疗策略以改善这些患者的预后。

研究设计与样本

  • 基于SEER数据库1988至2015年登记的软骨肉瘤患者进行回顾性分析。
  • 1988至2015年SEER数据库共登记5528例软骨肉瘤患者,经入选标准筛选后3374例纳入分析。
  • 采用卡方或Fisher精确检验比较人口学与临床病理数据,Logistic回归评估调整比值比。
  • 采用Kaplan-Meier曲线和log-rank检验估计总生存率,Cox比例风险模型进行单因素和多因素生存分析。
  • 进行系列敏感性分析评估最终Cox比例风险模型的稳健性。

主要发现

  • 44例(1.3%)在初诊时记录有区域淋巴结受累。
  • 骨外原发部位淋巴结转移报告率3%(13/426)vs 骨原发部位1%(31/2948),调整OR=2.9(95%CI 1.5-5.8;p=0.003)。
  • 肿瘤最大径≥8 cm者淋巴结转移报告率2%(26/1045)vs 最大径<8 cm者1%(10/1075),调整OR=2.9(95%CI 1.3-6.3;p=0.008)。
  • 分化较差者淋巴结转移报告率4%(24/608)vs 分化较好者1%(14/2308),调整OR=4.0(95%CI 2.0-8.2;p<0.001)。
  • 有远处转移者淋巴结转移报告率7%(14/203)vs 无远处转移者1%(30/3148),调整OR=3.5(95%CI 1.7-7.1;p=0.001)。

临床怎么用

  • 作者认为这些发现提示临床医生应更仔细检查软骨肉瘤患者的淋巴结转移情况。
  • 未来需要研究评估潜在治疗策略以改善这些患者的预后。

局限性

  • 鉴于该数据库报告的不准确性,可能低估了淋巴结转移患者的真实比例。
  • 未来需要研究评估潜在治疗策略以改善这些患者的预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regional lymph node involvement is thought to be rare in patients with chondrosarcoma, but its actual prevalence is unclear. Additionally, it is often not considered when prognostic factors are analyzed in patients with chondrosarcoma. However, it has been well established that lymph node involvement is a poor prognostic marker in patients with many types of bone and soft tissue sarcoma, including rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. Although lymph node metastases are rare among all sarcoma types, it is important to consider whether lymph node metastases should be assessed in patients with chondrosarcoma because these metastases may impact survival. QUESTIONS/PURPOSES: (1) What is the reported prevalence of regional lymph node involvement in patients with chondrosarcoma? (2) Do patients who have chondrosarcomas with regional lymph node involvement have different clinicopathologic presentations and survival than patients without regional lymph node involvement? (3) Is regional lymph node involvement independently associated with prognosis in patients with chondrosarcoma? METHODS: The data of patients with chondrosarcoma registered in the Surveillance Epidemiology and End Results database (SEER) (1988-2015) were analyzed for the reported prevalence of regional lymph node involvement and its relationship with clinicopathologic features and the 5-year overall survival rate. From 1988 to 2015, 5528 patients with chondrosarcoma were registered in the SEER database. After screening by the inclusion criterion-chondrosarcoma as the first primary tumor, diagnosis with histology confirmation, patients with active followup and available information about regional node status-3374 patients met the inclusion criteria and were analyzed. Demographics and clinicopathologic data were compared using chi-square or Fisher's exact tests. Logistic regression analysis was used to assess the adjusted odds ratio. The overall survival rate was estimated with Kaplan-Meier curves and log-rank tests. Univariate and multivariate analyses of overall survival were performed with Cox proportional hazard models. In addition, a series of sensitivity analyses were performed to assess the robustness of the final Cox proportional hazard model. RESULTS: Forty-four patients (1.3%) were recorded in the database as having regional lymph node involvement at the time of the primary diagnosis. Lymph node metastases were more likely to be reported in an extraskeletal primary site (3% [13 of 426] versus 1% [31 of 2948], adjusted odds ratio [OR] = 2.9, 95% CI, 1.5-5.8; p = 0.003) for bone primary sites and tumors with maximum diameter ≥ 8 cm (2% [26 of 1045] versus 1% [10 of 1075], adjusted OR = 2.9, 95% CI, 1.3-6.3; p = 0.008) and poorer differentiation (4% [24 of 608] versus 1% [14 of 2308], adjusted OR = 4.0, 95% CI, 2.0-8.2; p < 0.001), and in those with distant metastases (7% [14 of 203] versus 1% [30 of 3148], adjusted OR = 3.5, 95% CI, 1.7-7.1, p = 0.001). The 5-year overall survival rates of patients with and without regional lymph node involvement were 28% (95% CI, 15-42%) and 77% (95% CI, 75-78%), respectively (p < 0.001). After controlling for age, sex, race, grade, metastatic status, size, and histologic subtype, the presence of regional lymph node involvement was associated with poorer survival (hazard ratio, 2.20; 95% CI, 1.50-3.24; p < 0.001); this finding was confirmed in several sensitivity analyses. CONCLUSION: The prevalence of regional lymph node involvement in patients with chondrosarcoma was 1.3% in the SEER database. Although chondrosarcomas are rare, patients with chondrosarcomas who have regional node metastases have a poorer prognosis than those who have not reported to have them. This may underrepresent the true proportion of patients with lymph node metastases given the inaccuracies of reporting in this database, but we believe these findings indicate that clinicians should examine patients more carefully for chondrosarcoma with lymph node metastases. Future studies are needed to assess potential treatment strategies to improve the prognosis of these patients. LEVEL OF EVIDENCE: Level III, prognostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Wan L, Tu C, Li S, et al. Regional Lymph Node Involvement Is Associated With Poorer Survivorship in Patients With Chondrosarcoma: A SEER Analysis. Clin Orthop Relat Res. 2019. PMID: 31283732. doi:10.1097/CORR.0000000000000846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。